| Zeit | Aktuelle Nachrichten Sprache: 
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.10. | Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ) | 2 | Cision News | ||
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.09. | ELICERA THERAPEUTICS: Elicera clarifies status of the iTANK-platform patent application in the U.S. | 2 | Cision News | ||
| 19.09. | Elicera Therapeutics AB: Elicera clarifies status of the iTANK-platform patent application in the U.S. | 123 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 29.08. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 30 June 2025 | 152 | GlobeNewswire (Europe) | Second quarter (April-June 2025) 
	Operating loss amounted to SEK -2,892,341 (-5,841,409).
	Loss for the period amounted to SEK -2,732,070 (-5,622,779).
	Cash flow from operating activities totaled... ► Artikel lesen | |
| 25.08. | ELICERA THERAPEUTICS: Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy | 2 | Cision News | ||
| 25.08. | Elicera Therapeutics AB: Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy | 120 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 25.08. | Elicera Therapeutics AB: Elicera Therapeutics Continues Phase I/IIa CARMA Study with CAR T-Cell Therapy as Planned Following Safety Committee's Assessment in Cohort 2 | 125 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 28.05. | Elicera Therapeutics AB: Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company's oncolytic virus candidates, ELC-100 and ELC-201 | 160 | GlobeNewswire (Europe) | Gothenburg, May 28, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology... ► Artikel lesen | |
| 22.05. | Elicera Therapeutics AB: Elicera reports: Active lymphoma eliminated in two out of three patients in the first cohort of the CARMA study with iTANK-armed CAR T-cell therapy | 161 | GlobeNewswire (Europe) | Gothenburg, May 22, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 15.05. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 31 March 2025 | 164 | GlobeNewswire (Europe) | First quarter (January-March 2025) 
	Operating loss amounted to SEK -8,069,404 (-5,433,422).
	Loss for the period amounted to SEK -8,013,462 (-5,369,677).
	Cash flow from operating activities totalled... ► Artikel lesen | |
| 10.04. | Elicera Therapeutics AB: Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee's assessment of cohort 1 | 312 | GlobeNewswire (Europe) | Gothenburg, April 10, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 26.02. | Elicera Therapeutics - Positioned to deliver in cell and gene therapies | 369 | Edison Investment Research | Elicera Therapeutics is a cell and gene therapy company utilising its iTANK platform to develop immunotherapies for solid and bloodborne tumours. Its pipeline comprises two CAR-T therapies and two oncolytic... ► Artikel lesen | |
| 03.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-end Report 1 January - 31 December 2024 | 166 | GlobeNewswire (Europe) | Fourth quarter (October-December 2024) 
	Operating profit/loss amounted to SEK -2,911,958 (-5,212,694).
	Loss for the period amounted to SEK -2,603,242 (-4,749,222).
	Cash flow from operating activities... ► Artikel lesen | |
| 28.11.24 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 September 2024 | 122 | GlobeNewswire (Europe) | Third quarter (July-September 2024) 
	Operating profit/loss amounted to SEK -2,697,267 (-5,149,440).
	Loss for the period amounted to SEK -2,514,629 (-5,046,574).
	Cash flow from operating activities... ► Artikel lesen | 
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
 / Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt 
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 563,80 | +0,79 % | Paradigmenwechsel in der Glaukommedizin? NurExone erzielt dosisabhängige Wiederherstellung des Sehvermögens | ||
| BRAIN BIOTECH | 2,170 | -0,46 % | EQS-PVR: BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: BRAIN Biotech AG
BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung 
20.10.2025 / 15:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings  Company Exploring CDMO Expansion Opportunities in Southeast Asia  San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,986 | +1,34 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| BURCON NUTRASCIENCE | 1,470 | 0,00 % | Burcon NutraScience Corporation: Burcon Pea and Sunflower Proteins Outperform in Plant-based Cheese Study | Vancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (the "Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| CSL | 101,32 | -1,82 % | EQS-News: CSL wurde von der International Society for Pharmaceutical Engineering (ISPE) als Gesamtsieger der "2025 Facility of the Year Awards" ausgezeichnet | EQS-News: CSL
 / Schlagwort(e): Sonstiges
CSL wurde von der International Society for Pharmaceutical Engineering (ISPE) als Gesamtsieger der "2025 Facility of the Year Awards"... ► Artikel lesen | |
| MANNKIND | 4,885 | +1,69 % | MannKind: Stiller Gewinner im Kampf um die Lunge? | Nach einer Reihe operativer Fortschritte und der Übernahme von scPharmaceuticals richtet sich bei Aktionären der MannKind Corporation der Blick in die Zukunft. Die fundamentale Basis scheint geschaffen.... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 10,105 | -1,08 % | Ocular Therapeutix stock price target raised to $20 from $14 at TD Cowen | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,574 | +0,51 % | Oxford Nanopore Technologies: ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology | New adventitious viral agent (AVA) detection test offers rapid, sensitive, and affordable viral screening for biomanufacturers
ViruSure, a global leader in pathogen safety testing for biopharmaceuticals... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,050 | +9,89 % | Adaptimmune Therapeutics PLC - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| CODEXIS | 2,068 | +1,57 % | Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis Manufacturing Platform for Therapeutic siRNA Manufacturing | REDWOOD CITY, Calif., Oct. 29, 2025 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and... ► Artikel lesen | |
| CORMEDIX | 10,000 | +0,50 % | CorMedix, Inc.: CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025 | ||
| TELO GENOMICS | 0,033 | -4,35 % | Telo Genomics Corp.: American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition | Toronto, Ontario--(Newsfile Corp. - October 9, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for... ► Artikel lesen | |
| BIORA THERAPEUTICS | 0,001 | -100,00 % | NSE - BIORA THERAPEUTICS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |